Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells
AssigneesNational Yang-Ming University, National Taiwan University
InventorsZee-Fen Chang, Jim-Min Fang, Chun-Mei Hu, Ming-Tyng Yeh
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel TMPK inhibitor compositions and their methods of use. In particular, it relates to novel TMPK inhibitor compositions and therapeutics that lead to dUTP-mediated DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.
Claims52
A composition for inhibiting thymidylate kinase (TMPK) comprising a therapeutically effective amount of formula (I):
- wherein
- X═CH or N;
- Y═S, SO2, O, C═O, or NR5, wherein R5 is a substituent selected from the group consisting of hydrogen, a straight, branched or cyclic alkyl group, aralkyl, heteroaralkyl, heteroarakenyl, aryl, heteroaryl, optionally substituted with one or more substituents such as halogen, alkyl, hydroxyl, alkoxy, amino, nitro, cyano and carbonyl;
- R1═(CH2)nCOR6, wherein n is 0, 1, 2, or 3;
- and
- R2, R3, R4 and R6 are substituents independently selected from the group consisting of hydrogen, a straight, branched or cyclic alkyl group, a straight, branched or cyclic alkenyl group, a straight, branched or cyclic alkoxyl group, fluoroalkyl, perfluoroalkyl, aralkyl, arakenyl, arakynyl, heteroaralkyl, heteroarakenyl, heteroarakynyl, aryl, heteroaryl, optionally substituted with one or more substituents such as halogen, alkyl, hydroxyl, alkoxy, amino, nitro, cyano and carbonyl;
- or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(canceled)
A method for sensitizing cancer cells to the therapeutic effects of radiation therapy, chemotherapy or immunomodulatory therapy comprising exposing the cancer cells to an effective amount of an agent that inhibits TMPK activity.
Dependencies are inferred from the claim text.